AbbVie (ABBV) Tops Q4 EPS by 2c, FY20 EPS Guidance Beats

AbbVie (NYSE: ABBV) reported Q4 EPS of $2.21, $0.02 better than the analyst estimate of $2.19. Revenue for the quarter came in at $8.7 billion versus the consensus estimate of $8.7 billion.

GUIDANCE:

AbbVie sees FY2020 EPS of $9.61-$9.71, versus the consensus of $9.48.

• AbbVie is issuing its standalone GAAP diluted EPS guidance for the full-year 2020 of $7.66 to $7.76, representing growth of 46.0 percent at the midpoint. AbbVie expects to deliver standalone adjusted diluted EPS for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. The company's standalone 2020 adjusted diluted EPS guidance excludes $1.95 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

AbbVie expects standalone revenue growth approaching 8.0 percent on an operational basis.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Enphase Energy (ENPH) Misses Q1 EPS by 7c, misses on guidance
• Baker Hughes Company (BKR) Tops Q1 EPS by 4c, Beats on Revenue